TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03222505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honda Stride Assist Device ON
Description: Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honda Stride Assist Device ON
Description: Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Device Worn
Description: Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Device Worn
Description: Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
Study: NCT04131816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartHome
Description: The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
Study: NCT02421549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unpaired remote monitoring transmitter
Study: NCT02470689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerin cream
Description: Diacerin tablet solubule in ultraphil cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diacerin cream
Description: Diacerin tablet solubule in ultraphil cream
Study: NCT03251092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study: NCT01439867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Description: Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
Study: NCT01949636

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Study: NCT03142854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Description: participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
Study: NCT01511263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)
Description: Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
Description: Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year.
Study: NCT02979106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
Study: NCT03597984

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost-SIB on macroscopic metastases
Description: Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)
Study: NCT02294747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screw with Trochanteric Stabilization Plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screw without Trochanteric Stabilization Plate
Study: NCT00498472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-discharge NT-ProBNP based treatment
Description: Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is \>3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy.
Study: NCT02301377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiro PD personal spirometer
Study: NCT04227145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth Mobile
Description: It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with.
Study: NCT01156740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin G, Benzathine
Description: IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 750 mg/QD
Study: NCT01473277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BT-A (Dysport 500U), Triamcinolone acetonide
Description: All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BT-A (Dysport 500U), Triamcinolone acetonide
Description: All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment.
Study: NCT04237389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Index Guided endocardial catheter radiofrequency ablation
Description: Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive thoracoscopic surgical epicardial ablation.
Description: Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA.
Study: NCT02387151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stromal cells
Description: 2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
Study: NCT01780454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: T-Cell Depleting Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: B-Cell Depleting Agent

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Bone Marrow Depletion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic Irradiation
Study: NCT04525599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection
Study: NCT03121820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantinol tablets, 20 mg
Description: Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akatinol Memantine® tablets, 20 mg
Description: Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
Study: NCT00642525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast swallow radiography, endoscopy
Description: Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
Study: NCT01211301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food-based, Reduced Energy Diet Plan
Description: Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast 5 & 1 Plan
Description: Participants randomized to the Medifast group will enroll online in the Medifast 5 \& 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean \& Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are \>70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 \& 1 Plan. The Medifast 5 \& 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean \& Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 \& 1 Plan.
Study: NCT01483144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Description: Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine Placebo
Description: Eflornithine placebo \[three tablets orally once a day\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac 150 MG
Description: Sulindac \[one tablet orally once a day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac 150 MG
Description: Sulindac \[one tablet orally once a day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac placebo
Description: Sulindac placebo \[one tablet orally once a day\]
Study: NCT00295815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Description: 100-130 mg/m2, oral once, every 6 weeks until PD
Study: NCT03997487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOFTEE
Description: Smartphone app for taking quality images of conjunctivae
Study: NCT01901822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutured together
Description: The soft tissue and the allograft will be sutured together using a continuous sling suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutured separately
Description: The soft tissue and the allograft will be sutured separately using a continuous sling suture.
Study: NCT04027413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortisip compact protein
Description: (24% protein; 41% carbohydrate; 35% fat)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: preOp
Description: (100% carbohydrate).
Study: NCT00770471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01563913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill, taken for 1.5 years
Study: NCT02328937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality
Study: NCT02765789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (Immunosorba)
Description: Immunoadsorption as an alternative to plasma exchange
Study: NCT04232904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominous plane block (TAP Block)
Description: TAP block which is a peripheral nerve block preferred to postoperative pain management.
Study: NCT03564197

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-PD-L1
Description: 18F-PD-L1 PET/CT scan
Study: NCT00636415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
Study: NCT04742231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer
Description: Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer
Description: Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
Study: NCT00960362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
Study: NCT02328937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Study: NCT03181347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RYGB
Description: Roux-en-Y Gastric Bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SG
Description: Sleeve Gastrectomy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and behavioral
Description: Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
Study: NCT00919204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
Study: NCT00398281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03670251

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
Study: NCT00979953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03681743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT03755011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: white noise
Description: Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: normal ICU activity noise